RIKEN VITAMIN CO.,LTD. Q4 FY2025 earnings call

2024 Full Year Financial Performance

• Total company net sales hit an all-time high of 95.5 billion yen, with operating profit of 8.7 billion yen and ROE of 12.1%, which achieved all performance targets set in the prior mid-term management plan. The company reported a year-over-year decrease in operating profit, driven by rising labor costs (+0.97 billion yen), energy costs (+0.4 billion yen), advertising costs (+0.22 billion yen), logistics costs (+0.48 billion yen), and other SG&A increases (+0.78 billion yen), which offset 2.3 billion yen in profit growth from higher sales.
• The company sold 31 policy-held shareholdings for total proceeds of 5.5 billion yen, which reduced the ratio of policy-held shares to consolidated net assets to 19%, achieving the prior mid-term plan target of below 20%.
• Gains from sale of investment securities and real estate resulted in a 0.63 billion yen year-over-year increase in net income, even after accounting for a 0.68 billion yen special loss from retirement benefit system revisions. Total assets declined 5.7 billion yen, equity ratio increased 5.6pp to 70.1%, the company cancelled 3 million shares of treasury stock, and ownership by individual and foreign investors increased as cross-holding unwinding continued.

Prior Mid-Term Plan Review

• The company achieved all performance targets despite extreme volatility from COVID-19 and the Ukraine war, with operating profit hit the target in the second plan year, ROE reached 12.1% in the final year, and policy-held share reduction was completed.
• Unfinished key issues: The company's stock price has stalled below pre-2020 levels, with PBR still below 1x; factory aging and labor shortages make production restructuring unavoidable; and faster progress is needed to grow the overseas business, which is positioned as a core growth driver.

Mid-Term Management Plan 2027 (Current Plan) Strategic Framework

• The company extended its long-term vision goal to 2034, with quantitative targets of 135.0 billion yen in net sales, 13.5 billion yen in operating profit, 35% overseas sales ratio, and 10-12% ROE. For the current 2027 mid-term plan, the core themes are strengthening the domestic sustainable profit base and building a new structure for future overseas growth.
• Capital strategy focused on improving shareholder value and addressing low stock price: The company set targets of 110.0 billion yen in net sales, 10.0 billion yen in operating profit, 10%+ ROE, raised the target payout ratio to 40%+ to strengthen shareholder returns, will continue to opportunistically repurchase shares, will reduce the equity ratio from current levels, and targets to lower the policy-held share to net assets ratio to below 10%. Total planned cash allocation is 25.0 billion yen for capital investment, 12.4 billion yen for shareholder returns, and reserved funds for strategic investments including alliances and M&A. Capital investment will allocate 13.0 billion yen to domestic and 12.0 billion yen to overseas projects, with a focus on food modifiers.

Segment Strategic Priorities

• Domestic Food Business: Focus on developing and growing new market-creating products and revitalizing existing products for household food; strengthen offerings for growing markets including ready-to-eat/on-the-go meals, central kitchens, and frozen meals for food service; focus on solving client challenges from unstable sourcing, labor cost increases, and food waste, while expanding offerings for the health-focused market for processed food ingredients.
• Domestic Chemicals and Other Business: Concentrate development and sales resources on core strengths, especially plant-based chemical modifiers derived from the company's food modifier technology, to pursue domestic and global growth in this niche differentiated market.
• Overseas Business: The company will strengthen back-office support and regular talent rotation between domestic and overseas operations to accelerate growth, which had previously lagged due to under-resourced support functions. Growth will focus on food modifiers in Southeast Asia, China, and North America: A new food modifier plant started operations in May 2025 at Tianjin Riken in China, operated without adding headcount through labor-saving improvements; pork extract production capacity is being expanded in North America.

Non-Financial Strategy

• The company will continue to prioritize R&D-driven value creation (rooted in its origin as a spinoff from RIKEN Physical and Chemical Research Institute), combining short-term development and long-term research with active external collaboration for commercialization; for example, the company is developing large-scale sustainable seaweed aquaculture technology and partnering on blue carbon research.
• The company updated its human resources policy in January 2025 and will reform its personnel system under the 2027 plan to drive enterprise value growth; it will continue strengthening governance, especially for the overseas business, and continue policy-held share reduction and executive compensation reform.
• A CEO transition is scheduled for June 2025, with incoming CEO Mochizuki, who has extensive overseas experience, prioritizing accelerating overseas growth and building organizational psychological safety.

1. Domestic Food Business: Increased revenue but decreased profit overall. Breakdown by sub-segment:

• Household Foods: Increased revenue; new product lines (e.g., "Sprinkle Crunchy Wakame", "Mystery Dressing from Indian Curry Shop") saw strong sales growth, and the existing "Soy Dashi Stock" product also grew, while core established products like "Riken Non-Oil Dressing", "Wakame Soup" and "Fuero Wakame-chan" faced headwinds from price increases.
• Food Service: Increased revenue; price increase impacts were offset by new product adoption for food service and catering clients; volume declined from low-margin product rationalization, but profit structure improved. For food manufacturing clients, new product development activity increased and new adoption was gained, but the business was negatively impacted by consumer slowdown in purchasing of client products driven by heightened cost-saving sentiment.
• Processed Food Ingredients: Increased revenue; demand for core food modifiers for the baking industry remained steady, and sales volume stayed flat year-over-year despite price adjustments; overall vitamin demand slowed, but crocetin (marketed for sleep quality improvement) continued strong sales growth.

1. Domestic Chemicals and Other Business: Increased revenue and increased profit overall; food packaging wrap demand grew with higher inbound tourism and increased demand for food service and ready-to-eat meals, and the business is exploring new demand in categories like general merchandise and stationery; automotive industry client demand remained very weak.
2. Overseas Business: Increased revenue but decreased profit; the business prioritized volume growth amid intense competition with global rivals, but Q4 saw sales volume decline from worsening global economic conditions and further intensifying competition, leading to large profit impacts. North American pork extract business saw steady demand and growing sales.

• FY2025 (ending March 2026) guidance targets net sales of 100.0 billion yen (the first time the company has targeted sales over 100 billion yen) with operating profit of 8.5 billion yen, a 0.2 billion yen decrease year-over-year. Profit growth from higher sales (1.98 billion yen) is expected to be offset by rising labor costs (1.24 billion yen), logistics costs (0.51 billion yen), and other SG&A increases (0.51 billion yen).
• Overseas business is expected to see lower segment profit due to a change in segment profit adjustment calculation (allocating overseas expatriate expenses to overseas subsidiaries, which has no impact on consolidated operating profit) and higher depreciation expense.
• The company changed its dividend policy to target a 40% payout ratio, and plans a full-year dividend of 110 yen per share, a 16 yen increase.
• U.S. tariff impacts are not included in any current guidance or medium-term targets.
• The 2027 mid-term plan maintains the long-term direction of growth focused on expanding the overseas business as a core driver, with structured capital and strategic investment to achieve 2027 targets, while addressing structural challenges of factory aging and low market growth expectations for the domestic food market.

• Rising labor, energy, logistics, and raw material costs continue to pressure profit margins, even as the company implements price adjustments to offset these increases.
• Global economic slowdown could reduce demand for the company's specialty products, creating downside risk for earnings.
• The company's stock price has remained stalled below 1x PBR, as the market prices in low growth expectations for the domestic food market, low liquidity for the company's stock, and perceived weaknesses in balance sheet management.
• Factory aging and ongoing labor shortages have made production system restructuring unavoidable.
• U.S. import tariffs on Malaysian products could reduce exports of the company's food modifiers to the U.S., which account for half of the company's U.S. revenue, though pork extract production (the other half of U.S. revenue) sources most raw materials locally and is expected to see little direct impact. Indirect impacts from broader global economic slowdown are also a downside risk.
• Overseas business growth has lagged expectations due to historically insufficient back-office and support functions, requiring targeted investment to address.
• Automobile industry demand for the company's chemical products remains weak amid ongoing industry headwinds.
• Climate change increases raw material sourcing risk, as the company relies on a large number of natural raw materials, requiring increased buffer inventory for many inputs.

No formal question and answer section was included in the provided transcript.